Across TCGA pan-cancer cohorts, LINC01216 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC01216’s most consistent transcriptional readouts.
The strongest signal is observed in colon adenocarcinoma (COAD), where LINC01216 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC01216 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.
COAD are the cancer types where LINC01216 tumor–normal differential expression is most reproducible.